Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Top Cited Papers
Open Access
- 6 September 2009
- Vol. 17 (9), 1736-1743
- https://doi.org/10.1038/oby.2009.184
Abstract
The neurohormonal control of body weight involves a complex interplay between long‐term adiposity signals (e.g., leptin), and short‐term satiation signals (e.g., amylin). In diet‐induced obese (DIO) ...Keywords
This publication has 34 references indexed in Scilit:
- Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in ObesityDiabetes Care, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research studyAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Gastrointestinal regulation of food intakeJournal of Clinical Investigation, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiencyJournal of Clinical Investigation, 2002
- Leptin-Replacement Therapy for LipodystrophyNew England Journal of Medicine, 2002
- Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin DeficiencyNew England Journal of Medicine, 1999
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983